Patent ID: 9051367
Filing Date: 2015-06-09
Classification: A61K,C07K,G01N,Y10S

Abstract:
1. A method of treating a tauopathy in an individual, the method comprising administering to the individual a pharmaceutical composition comprising: a) a pharmaceutically acceptable excipient suitable for administration to a human; and b) a humanized antibody that specifically binds an epitope within an N-terminal portion of a human Tau polypeptide, wherein the humanized antibody comprises: a) a VH variant 1 comprising the amino acid sequence depicted in b) a VH variant 1 comprising the amino acid sequence depicted in c) a VH variant 1 comprising the amino acid sequence depicted in d) a VH variant 1 comprising the amino acid sequence depicted in e) a VH variant 2 comprising the amino acid sequence depicted in f) a VH variant 2 comprising the amino acid sequence depicted in g) a VH variant 2 comprising the amino acid sequence depicted in h) a VH variant 2 comprising the amino acid sequence depicted in i) a VH variant 3 comprising the amino acid sequence depicted in j) a VH variant 3 comprising the amino acid sequence depicted in k) a VH variant 3 comprising the amino acid sequence depicted in l) a VH variant 3 comprising the amino acid sequence depicted in m) a VH variant 4 comprising the amino acid sequence depicted in n) a VH variant 4 comprising the amino acid sequence depicted in o) a VH variant 4 comprising the amino acid sequence depicted in p) a VH variant 4 comprising the amino acid sequence depicted in